Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

Abstract

Average systemic exposure to fingolimod was similar after oral and intravenous administration. However, the acute decrease in lymphocyte counts was weaker after intravenous administration, likely because of lower blood levels of the active metabolite fingolimod-phosphate compared with oral administration.